In this interview from the 2011 American Society of Hematology (ASH) Annual Meeting, Dr. Bart Scott talks with Patient Power about Myelodysplastic Syndrome (MDS). He describes the disease and symptoms, including fatigue, shortness of breath, bruising, and increased infections. He also describes the demographic most commonly effected by the condition--Caucasian men, approximately 72 years old. For patients requiring red cell transfusions, several treatments have been FDA approved. Dr. Scott discusses Revlmid, or Lenalidomide, Vidaza, also known as Azacitidine and Decitabine, or Dacogen. Learn how the type of MDS determines the treatment received.